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Abstract
Background: Stearoyl-CoA desaturase-1 (SCD1) is an enzyme involved in lipid metabolism. In mice and humans its activity
has been associated with traits of the metabolic syndrome, but also with the prevention of saturated fatty acids
accumulation and subsequent inflammation, whereas for liver fat content inconsistent results have been reported. Thus,
variants of the gene encoding SCD1 (SCD1) could potentially modify metabolic risk factors, but few human studies have
addressed this question.
Methods: In a sample of 2157 middle-aged men and women randomly drawn from the Potsdam cohort of the European
Prospective Investigation into Cancer and Nutrition, we investigated the impact of 7 SCD1 tagging-single nucleotide
polymorphisms (rs1502593, rs522951, rs11190480, rs3071, rs3793767, rs10883463 and rs508384) and 5 inferred haplotypes
with frequency .5% describing 90.9% of the genotype combinations in our population, on triglycerides, body mass index
(BMI), waist circumference (WC), glycated haemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), gamma-
glutamyltransferase (GGT), alanine aminotransferase (ALT) and fetuin-A.
Results: No significant associations between any of the SNPs or haplotypes and BMI, WC, fetuin-A and hs-CRP were
observed. Associations of rs10883463 with triglycerides, GGT and HbA1c as well as of rs11190480 with ALT activity, were
weak and became non-significant after multiple-testing correction. Also associations of the haplotype harbouring the minor
allele of rs1502593 with HbA1c levels, the haplotype harbouring the minor alleles of rs11190480 and rs508384 with activity
of ALT, and the haplotype harbouring the minor alleles of rs522951, rs10883463 and rs508384 with triglyceride and HbA1C
levels and GGT activities did not withstand multiple-testing correction.
Conclusion: These findings suggest that there are no associations between common variants of SCD1 or its inferred
haplotypes and the investigated metabolic risk factors. However, given the results from animal models, heterogeneity of
human SCD1 warrants further investigation, in particular with regard to rare variants.
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Introduction
The human stearoyl-CoA desaturase-1 (SCD1) gene maps to
chromosome 10q24.31, has 6 exons and is remarkably expressed
in adipose tissue and the liver. It encodes the endoplasmatic
reticulum enzyme SCD1, which catalyses the conversion of the
saturated fatty acids (SFAs) palmitic and stearic, into the
monounsaturated fatty acids (MUFAs) palmitoleic and oleic
respectively [1]. These MUFAs are the major components of
triglycerides, likely due to its production within the environs of the
enzyme diacylglycerol acyltransferase (DGAT) [1]. Accordingly, it
has been suggested that the increased activity of SCD1 in the liver,
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could result in an excess assembly and accumulation of
triglycerides and subsequent development of hepatic steatosis
[2]. Further, the overflow of triglycerides could also be incorpo-
rated into very low density lipoprotein (VLDL) particles and
transported to adipose tissue and other sites, contributing to the
development of obesity [3]. Both these conditions have been
associated with insulin resistance [4]. Additionally, SCD1
deficiency has been associated with the reduced expression of
fatty acid synthesis genes [5] and the up-regulation of genes
involved in fatty acid b-oxidation [5,6]. In fact mice with a natural
or a targeted deletion of the SCD1 gene, have shown to be
protected against hypertriglyceridemia [7], hepatic steatosis [8–
10], obesity [3,5,8,11,12] and insulin resistance [11,13,14].
Conversely, there is also evidence that by channelling SFA, into
triglyceride pools, increased SCD1 activity may prevent from
lipoapoptosis [15], steatohepatitis [2] and inflammation [6,15–17].
Therefore, SCD1 seams to convey both, positive and negative
roles in the development of metabolic risk factors of cardiovascular
diseases.
Despite the strong scientific interest in SCD1, most of the
existing knowledge on its function comes from mice models [18].
Some human studies have provided indirect evidence of the role of
its activity (approximated as fatty acids product-to-precursor ratios
measured in serum, plasma, erythrocytes or adipose tissue), and
have proposed that its elevation might be associated with harmful
effects such as elevated plasma triglycerides levels [19,20], liver fat
[21–23], obesity [19,24], diabetes [25], high-sensitivity C-reactive
protein (hs-CRP) levels [26] and even with cardiovascular
mortality [27]. Conversely the scarce human studies investigating
the tissue-specific activity and expression of SCD1, suggest that
elevated SCD1 activity may protect from liver fat accumulation
[28,29]. Further, the impact of SCD1 heterogeneity on metabolic
risk factors, has so far only been investigated in four human studies
with focus on diabetes and obesity [30,31], metabolic syndrome
(MetS) [32] or inflammation [33]. Thus, a case control study in
men and women from the United Kingdom, found no associations
between 6 SCD1 single nucleotide polymorphisms (SNPs) or its
inferred haplotypes and diabetes, body mass index (BMI) or waist-
to-hip ratio [30]; a cross-sectional study in Swedish elderly men
reported that 4 out of 8 SCD1 tagging SNPs (tag-SNPs) related to
decreased BMI and waist circumference (WC), and increased
insulin sensitivity [31]; the haplotype consisting of the rare alleles
of these SNPs was also associated with decreased WC; a cross-
sectional study in Costa Rican middle-aged men and women
reported that 1 out of 7 SCD1 tag-SNPs was associated with an
increased prevalence of MetS, and among women, also with
elevated systolic blood pressure and fasting blood glucose levels
[32]. Also 2 haplotypes carrying the minor allele of this SNP were
associated with elevated prevalence of MetS; finally a cross-
sectional study in European and Asian young adults found 1 out of
10 tag-SNPs to be associated with CRP levels [33].
In the Potsdam cohort of the European Prospective Investiga-
tion into Cancer and Nutrition (EPIC-Potsdam), we investigated
the impact of common genetic variation in SCD1, captured by
means of 7 tag-SNPs and their inferred haplotypes, on the
modulation of 8 metabolic risk factors related to the activity of
SCD1. The investigated traits were plasma triglyceride levels,
traits related to obesity (BMI and waist circumference (WC)),
glucose metabolism (glycated haemoglobin (HbA1c)) and chronic
inflammation (hs-CRP), and, for the first time, crude estimates of
the presence of liver fat (the liver enzymes gamma-glutamyltrans-
ferase (GGT) and alanine amino transferase (ALT) [34,35]), and
fetuin-A, a biomarker which has been associated with fat
accumulation in the liver [36–40] as well as with insulin resistance,
type 2 diabetes and cardiovascular events [40–42].
Methods
Ethics Statement
Written informed consent was obtained from all study
participants, and approval was given by the Ethics Committee of
the Medical Association of the State of Brandenburg, Germany.
Study Population
EPIC-Potsdam comprises 27548 individuals (10904 men and
16644 women) from the general population of the Potsdam area in
Germany. Men were mainly aged 40–65 and women 35–65 years
old at recruitment, which took place between 1994 and 1998 [43].
The baseline examination included a personal interview and a
questionnaire on sociodemographic and lifestyle characteristics
and prevalent diseases as well as anthropometric measurements
[44]. The associations of 7 SCD1 tag-SNPs and their inferred
haplotypes with anthropometric and metabolic markers were
investigated in a random sample of 2500 individuals (subcohort)
drawn from the participants in the total cohort who had provided
blood samples at baseline, following a cross-sectional design. After
exclusion of individuals with missing covariates or genotype data,
the final study population comprised 2157 participants. Fasting
was not required at the time of blood draw, however, 615
participants were in fasting state for at least 8 h.
Laboratory Analyses
From all the study participants a 30 mL sample of venous blood
was collected, fractionated into serum, plasma, buffy coat and
erythrocytes, and stored in liquid nitrogen until the time of
analysis. Plasma levels of triglycerides, HbA1c, GGT, ALT, fetuin-
A, hs-CRP, total cholesterol and high density lipoprotein (HDL)-
cholesterol were determined with the automatic ADVIA 1650
analyser (Siemens Medical Solutions, Erlangen, Germany) at the
Department of Internal Medicine of the University of Tu¨bingen,
Germany, in 2007.
SNP Selection and Genotyping
Seven SCD1 tag-SNPs (ordered according to chromosomic
location: rs1502593, rs522951, rs11190480, rs3071, rs3793767,
rs10883463 and rs508384) were identified in the HapMap 22/
phaseII CEU population data (Utah residents with ancestry from
northern and western Europe) [45] using stringent criteria (minor
allele frequency (MAF) .0.05 and pairwise r2$0.8) by means of
the Tagger software [46] implemented in the version 4.2 of
Haploview [47]. The tagged region comprised the coding region
of SCD1 as well as a 4.1 Kb upstream (promoter) and 4.3 Kb
downstream (39 untranslated) region of the gene. Six SNPs were
located in intronic sites and one in the 39 untranslated region
(rs508384). Genotyping of whole genome amplified DNA samples
was performed with a 7900HT Sequence Detection System with
TaqMan assays (Applied Biosystems, Foster City, CA, USA) at the
Max Delbru¨ck Centre for Molecular Medicine, Berlin, Germany,
in 2009. The average genotyping success rate in the 7 SNPs was
.98%.
Statistical Analyses
Normality of variables was tested by estimating their skewness
and kurtosis, by comparing their means and median values and by
plotting their distributions in histograms. To better reach
normality of their distributions, triglycerides, GGT, ALT and
hs-CRP were natural log-transformed and HbA1c inverse-
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transformed, and were used like that in all analyses. Hardy–
Weinberg equilibrium (HWE) of the SNPs was tested using the x2
test. Linkage disequilibrium between SNPs was assessed with the r2
measure using Haploview 4.2 [47]. Each SNP was coded as 0, 1
and 2 according to the number of minor alleles a participant
carried. Analysis of covariance considering the additive, dominant
and recessive genetic models was used to assess the associations
between the SNPs (independent variables) and triglycerides, BMI,
Table 1. Baseline characteristics of the EPIC-Potsdam subcohort and separately for men and women.
Subcohort Men Women P value a
Characteristic (N=2157) (N=819; 38%) (N=1338; 62% )
Age (years) 50.369.0 52.4 (51.8–53.0) 49.0 (48.5–49.4) ,0.0001
Educational attainment (%):
Vocational school or less 37.4 30.8 41.5 ,0.0001
Technical school 24.9 15.9 30.4 ,0.0001
University degree 37.7 53.4 28.1 ,0.0001
Physical activity (%):
,2 hours/week 75.9 74.7 76.7 0.3
$2 hours/week 24.1 25.3 23.3 0.3
Smoking status (%):
Current $20 cigarettes/d 6.3 11.3 3.2 ,0.0001
Current ,20 cigarettes/d 14.9 16.7 13.8 0.07
Former #5 years 7.5 9.5 6.3 0.006
Former .5 years 24.4 35.3 17.7 ,0.0001
Never 46.9 27.2 59.0 ,0.0001
Alcohol intake (%):
Men: = 0 g/d; women: = 0 g/d 0.05 0.1 0.0 0.3
Men: .0–12 g/d; women: .0–6 g/d 47.2 36.4 53.9 ,0.0001
Men: .12–24 g/d; women: .6–12 g/d 24.7 26.1 23.9 0.3
Men: .24 g/d; women: .12 g/d 28.0 37.5 22.2 ,0.0001
Use of medication (%):
Antidiabetic 2.6 3.5 2.0 0.03
Antihypertensive 19.3 19.6 19.2 0.8
Lipid lowering medication 5.1 5.7 4.7 0.3
Body mass index (kg/m2) 26.164.3 26.6 (26.3–26.8) 25.8 (25.6–26.1) 0.0002
Waist circumference (cm) 85.8612.9 93.4 (92.6–94.1) 81.2 (80.6–81.7) ,0.0001
Triglyceridesb (mg/dL) 90.2 (64.9–126.5) 109.3 (102.1–117.0) 82.1 (77.6–86.7) ,0.0001
Gamma-glutamyltransferase (U/L) 16.8 (11.0–30.8) 28.3 (26.8–29.9) 14.4 (13.8–15.0) ,0.0001
Glutamic-pyruvate transaminase (U/L) 18.7 (14.3–26.4) 25.9(25.1–26.7) 16.8 (16.4–17.3) ,0.0001
Fetuin-Ac (mg/dL) 0.2560.06 0.25 (0.24–0.25) 0.25 0.25–0.26) 0.03
Glycated haemoglobin (%) 6.4 (6.1–6.8) 6.5 (6.4–6.6) 6.4 (6.4–6.5) 0.002
Hs-C-reactive protein (mg/L) 0.8 (0.2–2.1) 0.6 (0.6–0.7) 0.8 (0.6–0.7) ,0.0001
Minor allele frequencyd (%):
rs1502593 (C.T) 44 45 43 0.2
rs522951 (G.C) 46 46 47 0.6
rs11190480 (A.G) 9 9 9 0.6
rs3071 (T.G) 35 35 34 0.8
rs3793767 (T.C) 38 36 39 0.2
rs10883463 (T.C) 8 8 8 0.7
rs508384 (C.A) 17 17 17 1.0
Subcohort: Mean 6 SD, %, or median (25th percentile; 75th percentile), all such values. Men and women: mean and 95% confidence interval (CI) or %. Results
obtained using analysis of covariance, all variables other than age are adjusted for age.
aP value for the difference between men and women.
bbased on the 615 participants fasting at blood draw.
cbased on 2077 participants due to missing biomarker data.
dAlleles given in brackets (most .less frequent allele).
doi:10.1371/journal.pone.0048338.t001
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Table 2. Age- and sex-adjusted association analyses between the 7 SCD1 tag-SNPs and the 8 investigated metabolic traits: the
EPIC-Potsdam Study.
Triglyceridesa, b
(mg/dL)
BMI c
(kg/m2)
WC c
(cm) HbA1c d (%) GGT b (U/L) ALT b (U/L)
Fetuin-A c, e
(mg/dL)
hs-CRP b
(mg/L)
rs1502593 (n)
0 (679) 96.45 (89.23–104.26) 26.2260.16 87.4760.41 6.48 (6.43–6.53) 20.13 (18.97–21.35) 20.52 (19.81–21.25) 0.2560.002 0.73 (0.66–0.81)
1 (1072) 92.49 (86.98–98.34) 26.2560.13 87.3660.33 6.50 (6.46–6.55) 20.24 (19.31–21.21) 20.85 (20.28–21.44) 0.2560.002 0.72 (0.67–0.79)
2 (406) 96.46 (87.67–106.14) 26.0060.21 86.6360.53 6.45 (6.39–6.52) 20.27 (18.79–21.87) 21.52 (20.57–22.50) 0.2660.003 0.73 (0.63–0.83)
Padd 0.89 0.47 0.25 0.63 0.87 0.11 0.19 0.88
Pdom 0.53 0.83 0.53 0.80 0.87 0.24 0.75 0.86
Prec 0.63 0.30 0.18 0.25 0.93 0.14 0.06 0.96
rs522951 (n)
0 (607) 94.06 (86.85–101.88) 26.0360.17 86.7960.44 6.47 (6.41–6.52) 19.93 (18.73–21.21) 20.96 (20.20–21.75) 0.2560.002 0.72 (0.64–0.80)
1 (1095) 95.22 (89.54–101.26) 26.2360.13 87.2660.32 6.50 (6.46–6.54) 20.46 (19.53–21.43) 20.88 (20.31–21.46) 0.2560.002 0.73 (0.67–0.79)
2 (455) 93.32 (85.14–102.30) 26.3160.20 87.8760.50 6.49 (6.43–6.55) 19.98 (18.59–21.47) 20.73 (19.87–21.64) 0.2560.003 0.73 (0.64–0.83)
Padd 0.93 0.28 0.10 0.50 0.90 0.70 0.46 0.82
Pdom 0.90 0.27 0.20 0.35 0.60 0.78 0.20 0.80
Prec 0.77 0.52 0.17 0.90 0.72 0.73 0.87 0.91
rs11190480 (n)
0 (1787) 93.97 (89.60–98.56) 26.2360.10 87.3860.26 6.49 (6.46–5.52) 20.30 (19.57–21.06) 21.08 (20.62–21.54) 0.2560.001 0.73 (0.68–0.78)
1 (357) 96.89 (87.11–107.77) 26.0560.22 86.6660.57 6.46 (6.39–6.53) 19.93 (18.39–21.61) 19.85 (18.92–20.82) 0.2560.003 0.72 (0.63–0.83)
2 (13) 114.86 (39.83–331.24) 25.6061.16 86.7162.95 6.66 (6.29–7.06) 15.46 (10.14–23.57) 21.67 (16.88–27.81) 0.2460.015 0.59 (0.28–1.25)
Padd 0.56 0.39 0.25 0.63 0.41 0.05 0.35 0.78
Pdom 0.58 0.42 0.24 0.49 0.54 0.03 0.36 0.85
Prec 0.72 0.61 0.85 0.38 0.21 0.77 0.73 0.59
rs3071 (n)
0 (944) 95.09 (89.07–101.53) 26.3660.14 87.6560.35 6.47 (6.43–6.52) 20.64 (19.63–21.70) 20.75 (20.15–21.38) 0.2560.002 0.77(0.71–0.84)
1 (936) 94.84 (88.81–101.29) 25.9660.14 86.7960.35 6.50 (6.45–6.54) 19.76 (18.79–20.78) 20.86 (20.25–21.49) 0.2560.002 0.68(0.63–0.75)
2 (277) 91.32 (81.28–102.61) 26.4260.25 87.4960.64 6.52 (6.44–6.60) 20.30 (18.53–22.25) 21.30 (20.17–22.48) 0.2560.003 0.73(0.63–0.86)
Padd 0.62 0.47 0.36 0.28 0.46 0.46 0.92 0.22
Pdom 0.79 0.10 0.13 0.32 0.27 0.62 0.86 0.08
Prec 0.54 0.34 0.69 0.46 0.92 0.43 0.64 0.90
rs3793767 (n)
0 (845) 95.94 (89.64–102.68) 26.1760.15 87.2160.37 6.47 (6.42–6.51) 20.50 (19.45–21.61) 21.05 (20.41–21.72) 0.2560.002 0.71 (0.65–0.78)
1 (998) 94.63 (88.81–100.83) 26.1560.13 87.1560.34 6.51 (6.47–6.55) 20.40 (19.43–21.41) 20.83 (20.23–21.44) 0.2560.002 0.74 (0.68–0.81)
2 (314) 89.68 (79.88–100.67) 26.4160.24 87.7460.61 6.48 (6.41–6.56) 18.86 (17.30–20.57) 20.51 (19.49–21.59) 0.2560.003 0.73 (0.62–0.84)
Padd 0.37 0.50 0.57 0.50 0.17 0.38 0.97 0.65
Pdom 0.56 0.81 0.86 0.26 0.49 0.48 0.50 0.50
Prec 0.34 0.33 0.38 0.81 0.09 0.47 0.32 0.97
rs10883463 (n)
0 (1840) 94.64 (90.34–99.15) 26.1860.10 87.2160.25 6.49 (6.46–6.52) 19.88 (19.17–20.61) 20.78 (20.34–21.23) 0.2560.001 0.73 (0.68–0.78)
1 (304) 89.89 (79.74–101.33) 26.2460.24 87.3960.61 6.49 (6.41–6.56) 22.43 (20.56–24.48) 21.35 (20.27–22.48) 0.2560.003 0.72 (0.62–0.85)
2 (13) 160.99 (100.50–257.90) 27.4961.16 90.7762.95 6.10 (5.80–6.44) 17.85 (11.72–27.19) 22.48(17.52–28.85) 0.2360.017 0.61 (0.29–1.28)
Padd 0.76 0.50 0.48 0.36 0.04 0.27 0.85 0.81
Pdom 0.80 0.64 0.63 0.62 0.02 0.30 0.99 0.88
Prec 0.03 0.26 0.23 0.03 0.56 0.56 0.32 0.63
rs508384 (n)
0 (1489) 93.94 (89.21–98.93) 26.1860.11 87.2760.28 6.50 (6.46–6.53) 20.01 (19.22–20.83) 21.01 (20.51–21.51) 0.2560.002 0.73 (0.68–0.78)
1 (610) 93.61 (86.21–101.65) 26.2460.17 87.1660.43 6.47 (6.42–6.53) 20.66 (19.42–21.98) 20.55 (19.81–21.31) 0.2560.002 0.74 (0.66–0.82)
2 (58) 119.44 (92.43–154.35) 26.1860.55 87.9061.40 6.44 (6.27–6.62) 20.67 (16.92–25.25) 20.85 (18.52–23.48) 0.2560.008 0.64 (0.45–0.91)
Padd 0.36 0.81 0.96 0.36 0.40 0.39 0.27 0.86
Pdom 0.69 0.78 0.92 0.39 0.38 0.33 0.31 0.95
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WC, HbA1c, GGT, ALT, fetuin-A and hs-CRP (dependent
variables). Haplotypes were constructed to test whether multiple
genetic variants of SCD1 or a possible unobserved risk variant
captured by the haplotypes, modulated the investigated traits.
Haplotype frequencies were estimated based on the observed
unphased genotypes by the expectation-maximization algorithm
[48]. The effects of a particular haplotype load (0, 1 or 2 copies)
were tested also by means of a regression-based analysis
(ANCOVA) as suggested by Zaykin et al. [49]. Analyses were
restricted to participants with a probability of 49–50% to carry one
copy of the haplotype, or 100% probability to carry either none or
two copies. Only haplotypes with frequencies .5% were
considered. The additive, dominant and recessive models were
examined. Analyses for triglycerides were performed only in
participants who were fasting at the time of blood draw. Data are
reported as means and standard errors, geometric means and 95%
confidence intervals (CI) or inverse and 95% CI as appropriate.
Regression coefficients and standard errors (SE) were also
estimated. All analyses were adjusted for age and sex. Further
(mutual) adjustment for known cardiovascular risk factors includ-
ing smoking status (never smoker, former smoker, current smoker
,20 cigarettes per day, current smoker $20 cigarettes per day),
sports activity (,2 h/wk versus $2 h/wk), educational attainment
(vocational school or less, technical school, university), BMI
(continuous), WC (continuous), alcohol consumption (men: = 0 g/
d, .0 to 12 g/d, .12 to 24 g/d; .24 g/d; women: = 0 g/d, .0
to 6 g/d, .6 to 12 g/d; .12 g/d), prevalent diabetes, prevalent
hypertension, total cholesterol, HDL cholesterol and hs-CRP)
were also explored for the tag-SNPs. Effect modification by sex
was evaluated by modeling the cross product term sex times
genotype or haplotype, along with main effects (in the age-adjusted
general linear model). All statistical analyses were performed using
SAS Enterprise Guide 4.3 (SAS Institute Inc., Cary, NC, USA).
Power calculations were performed with Quanto [50] consid-
ering an additive model, a desirable power of 80%, a two-sided a
of 0.05, the means and standard deviations of the traits in the
subcohort (non-normal variables were transformed to normality)
and the genotype frequencies of the least (rs10883463, MAF=8%)
and most (rs522951, MAF=46%) common tag-SNPs. The
detectable differences in our study ranged between 0.1 and
0.2 SD for BMI, WC, GGT, ALT, fetuin-A, hs-CRP and HbA1c
and between 0.2 and 0.3 SD for triglycerides. Conservative
Bonferroni correction for multiple comparisons was performed
(P Bonferroni = a/(n individual hypothesis tested) = 0.05/((7 SNPs +5
haplotypes)63 genetic models per SNP68 traits investigated). The
corrected significance threshold was P Bonferroni = 0.0002.
Results
Characteristics of the Study Population
Demographic, lifestyle, clinical, biochemical and genetic char-
acteristics of the study population are given in Table 1, both for
the subcohort and separately for men and women. Men (38%)
were older than women due to sampling strategy. After adjusting
for age, they also showed to smoke and drink more and to take
more often antidiabetic medication. Further their BMI, WC and
their activities of GGT and ALT were higher. They were more
likely to be higher educated and also had lower hs-CRP levels than
women. The genotype frequency of all SCD1 tag-SNPs followed
HWE (P.0.05), their allele frequencies were comparable to those
observed in HapMap 22/phaseII CEU population data [45] and
did not differ among sexes. Table S1 presents further information
regarding genotype and allelic frequencies of the tag-SNPs across
the EPIC-Potsdam subcohort and separately for men and women.
Linkage disequilibrium values (r2) between each pair of tag-
SNPs ranged from 0 to 0.66. Five haplotypes inferred from the
genotyped SNPs, with frequency .5% described 90.9% of the
genotype combinations in our population: A-B-A-A-B-A-A
(34.1%); B-A-A-B-A-A-A (29.8%), B-A-A-A-A-A-A (11.0%), A-
A-B-A-A-A-B (8.6%) and A-B-A-A-A-B-B (7.4%) (Haplotypes are
composed of variants rs1502593 (C.T), rs522951 (G.C),
rs11190480 (A.G), rs3071 (T.G), rs3793767 (T.C),
rs10883463 (T.C), rs508384 (C.A) in that order; A indicates
common allele, B indicates rare allele).
Associations between SCD1 Tag-SNPs and Inferred
Haplotypes and the Investigated Traits
No significant effect modifications by sex were found for any of
the tag-SNPs or inferred haplotypes on the investigated traits, thus
results are presented combined for men and women.
Table 2 shows results for age- and sex-adjusted mean values of
the 8 investigated metabolic traits for each of the 7 SCD1 tag-
SNPs. No significant associations were found between rs1502593,
rs522951, rs3071, rs3793767 or rs508384 and any of the
investigated traits. Also no significant associations were found
between any of the investigated SNPs and fetuin-A, BMI, WC or
hs-CRP. However, carriers of the rs11190480 rare allele,
presented slightly lower activities of ALT in a dominant fashion
(19.91 vs. 21.07 U/L, P= 0.03). Carriers of the rs10883463 rare
allele, showed higher triglycerides (160.97 vs. 94.02 mg/dL,
P= 0.03) and lower HbA1c levels (6.10 vs. 6.49%, P= 0.03) in a
recessive fashion, and slightly higher activities of GGT (22.22 vs.
19.88 U/L, P= 0.02) in a dominant fashion. Results were weak in
precision, as shown by the wide confidence intervals, and after
applying the Bonferroni correction for the multiple hypothesis
tested (P Bonferroni = 0.0002), none of them remained significant.
Table 2. Cont.
Triglyceridesa, b
(mg/dL)
BMI c
(kg/m2)
WC c
(cm) HbA1c d (%) GGT b (U/L) ALT b (U/L)
Fetuin-A c, e
(mg/dL)
hs-CRP b
(mg/L)
Prec 0.07 0.98 0.64 0.58 0.82 0.99 0.49 0.46
Each SNP is coded as 0, 1 and 2 according to the number of minor alleles a participant carries.
abased on the 615 participants fasting at blood draw.
bgeometric means and (95% CI);
cmeans and standard error;
dinverse and (95% CI),
ebased on 2077 participants due to missing biomarker data. All the reported significance levels are nominal P values and are not adjusted for multiple comparisons.
Padd, P for trend or P for the additive model; Pdom, P value for the dominant model. Prec, P value for the recessive model.
doi:10.1371/journal.pone.0048338.t002
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After further (mutual) adjustment of the statistical models for
known cardiovascular risk factors, results remained essentially
similar (table S2). Also they were not modified by adjustment for
fasting status or exclusion of participants taking lipid-lowering or
antidiabetic medication.
Table 3 shows results for age- and sex-adjusted mean values of
the investigated metabolic traits for each of the 5 SCD1 haplotypes.
No associations between the two most common haplotypes and
the investigated variables became apparent. Homozygotes for
haplotype B-A-A-A-A-A-A harbouring the minor allele of the SNP
rs1502593 presented lower HbA1c levels (6.03 vs. 6.49%,
P= 0.003). Carriers of haplotype A-A-B-A-A-A-B harbouring the
minor alleles of the SNPs rs11190480 and rs508384 exhibited
slightly lower activities of ALT in a dominant fashion (19.85 vs.
21.08 U/L, P= 0.02). Carriers of haplotype A-B-A-A-A-B-B
harbouring the minor alleles of the SNPs rs522951, rs10883463
and rs508384 showed higher triglyceride values 179.77 vs.
94.08 mg/dL and lower HbA1C levels (6.09 vs. 6.49%,
P= 0.03) in a recessive fashion, and higher GGT activities
(22.24 vs. 19.93 U/L, P= 0.03) in a dominant fashion. However,
after correction for multiple testing, also none of these results
remained significant. Table S3 summarizes all of these results in
the form of age- and sex-adjusted regression coefficients.
Discussion
In the present study of a middle-aged sample of German men
and women, we evaluated the impact of 7 SCD1 tag-SNPs and 5
inferred haplotypes on MetS related traits on suggested crude
estimates of the presence of liver fat and on inflammation. Our
study is, so far, the largest performed in a European population,
and also the first to report association results between SCD1
genetic variants and liver parameters. We hypothesized that any
functional variant affecting the activity of SCD1 would possibly
result in the modulation of one or more of the traits. At most, we
found some associations weak in magnitude, precision, and
statistical significance, which after conservative Bonferroni-cor-
rection for the number of traits, SNPs and haplotypes tested, did
not remain significant, thus being suggestive of chance findings.
Four previous studies in humans have investigated the
association of SCD1 polymorphisms with different metabolic traits
[30–33]. In a UK case-control study of 608 cases and 600 controls,
Liew et al. [30] reported upon the association of 6 SCD1 SNPs
with type 2 diabetes, BMI and waist-to-hip ratio. Three of these
SNPs were in common or highly linked to SNPs of our study:
rs670213 (a good proxy for rs522951, r2 = 0.87 according to
HapMap data for Caucasians of European origin [45], rs3071 and
rs11598233 (a perfect proxy for rs3793767, r2 = 1 [45]). Consistent
with our results, they also reported no significant associations.
Warensjo¨ et al. [31] investigated associations of 8 SCD1 tag-SNPs
with obesity and insulin sensitivity in 1143 Swedish elderly men.
Five of these SNPs, were in common or highly linked to SNPs of
our study, rs3870747 (linked with rs1119040, r2 = 0.94 [45]),
rs3071, rs3793767, rs10883463 and rs508384. In line with our
results, they found a tendency of rs10883463 carriers towards
increased insulin sensitivity, and no significant associations for
rs3870747 and rs3793767. In contrast, they reported lower WC in
carriers of rs10883463, lower WC and higher insulin sensitivity in
homozygotes for rs508384 rare allele and lower insulin sensitivity
in heterozygotes for rs3071. This last association was also
inconsistent with the results from Liew et al. [30]. Compared
with our study population, the study of Warensjo¨ et al. [31] was
smaller and included only elderly men. However, we found no
significant sex interaction for any of the SNPs with any of the
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studied phenotypes, and further all our association analyses were
adjusted for age, what makes the overall evidence for an
association of SCD1 genetic variability with WC and insulin
sensitivity less consistent. Recently, Gong et al. [32] analysed the
association of 7 SCD1 tag-SNPs with MetS prevalence in 2152
Costa Rican adult men and women. Only one SNP, rs1502593,
was found to be associated with MetS. This SNP was also analysed
in our population. In line with our results, they did not observe
significant associations between rs1502593 and triglyceride levels
or WC. They did point out a borderline association of rs1502593
with elevated fasting blood glucose levels among women. In our
population we found no significant associations for this SNP.
Homozygotes for the haplotype harbouring its minor allele showed
lower HbA1c levels, measure of the average plasma glucose levels
over prolonged periods of time, but this association did not
withhold after multiple-testing correction. We cannot discard the
possibility that the different ethnic origin may explain the different
findings. Finally, Stryjecki et al. [33] examined the relationships
between 10 SCD1 tag-SNPs and CRP levels in 279 European and
249 Asian young adults. Only one SNP located 9 Kb upstream
SCD1, and thus not included in our study, was associated with
CRP levels, and only among females of both groups.
Limitations of our study should be mentioned. It is possible that,
due to sample size limitations we were not able to detect minor
contributions of the alleles. This limitation was stronger in the case
of the association analyses for triglycerides levels, as fasting data
was available only for about one third of the population. Thus
while some of our results could represent a replication for certain
relationships inspected in the four association studies that precede
ours [30–33], to evaluate the outcome of our work, further studies
in independent cohorts analysing the same SNPs, or those in
perfect linkage disequilibrium, are necessary [51]. Also, we cannot
exclude the possibility that a rare causal variant exists within the
typed region but was not picked up by the chosen markers.
In summary, our findings suggest that common variants of
SCD1 do not modulate the investigated metabolic factors in this
European population. However, given its biological relevance, the
still scarce number of studies available and the inconsistency of
their results, genetic heterogeneity of human SCD1 in relation to
impaired metabolism rewards further investigation in independent
study populations, in particular with regard to rare variants of
SCD1.
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